Background-MicroRNAs (miRs) participate in many cardiac pathophysiological processes, including ischemia/reperfusion (I/R)-induced cardiac injury. Recently, we and others observed that miR-494 was downregulated in murine I/R-injured and human infarcted hearts. However, the functional consequence of miR-494 in response to I/R remains unknown. Methods and Results-We generated a mouse model with cardiac-specific overexpression of miR-494. Transgenic hearts and wild-type hearts from multiple lines were subjected to global no-flow I/R with the Langendorff system. Transgenic hearts exhibited improved recovery of contractile performance over the reperfusion period. This improvement was accompanied by remarkable decreases in both lactate dehydrogenase release and the extent of apoptosis in transgenic hearts compared with wild-type hearts. In addition, myocardial infarction size was significantly reduced in transgenic hearts on I/R in vivo compared with wild-type hearts. Similarly, short-term overexpression of miR-494 in cultured adult cardiomyocytes demonstrated an inhibition of caspase-3 activity and reduced cell death on simulated I/R. In vivo treatment with antisense oligonucleotide miR-494 increased I/R-triggered cardiac injury relative to the administration of mutant antisense oligonucleotide miR-494 and saline controls. We further identified that 3 proapoptotic proteins (PTEN, ROCK1, and CaMKII␦) and 2 antiapoptotic proteins (FGFR2 and LIF) were authentic targets for miR-494. Importantly, the Akt-mitochondrial signaling pathway was activated in miR-494 -overexpressing myocytes. Conclusions-Our findings suggest that although miR-494 targets both proapoptotic and antiapoptotic proteins, the ultimate consequence is activation of the Akt pathway, leading to cardioprotective effects against I/R-induced injury. Thus, miR-494 may constitute a new therapeutic agent for the treatment of ischemic heart disease. (Circulation. 2010; 122:1308-1318.)
I schemic heart disease, a leading cause of death worldwide, is the most common consequence of coronary artery disease. 1, 2 Although reperfusion of an occluded human coronary is effective for reducing overall mortality, it is now recognized that restoration of the blood flow through the previously ischemic myocardium can yield additional reperfusion injury, including cardiomyocyte dysfunction and cell death. 3 The cellular mechanisms underlying ischemia/reperfusion (I/R)-induced injury are complex and involve a multitude of signaling pathways and molecular players. 4 Therefore, it would be rational to develop an effective pharmacological or genetic agent aimed at multiple molecular targets. MicroRNAs (miRs), a new class of Ϸ22-nt non-protein-coding single-strand RNAs, have emerged as regulators that control the expression of hundreds of proteins. 5 As a consequence, they may widely influence the signaling networks leading to pathological/physiological responses such as myocardial I/R injury. Indeed, accumulating evidence has shown that miRs are involved in the process of cardiac remodeling and heart failure via regulation of numerous effectors within the same functional pathway. 6, 7 Thus, miRs might be attractive nodal therapeutic targets for the treatment of heart disease.
Clinical Perspective on p 1318
One specific miR, miR-494, has recently garnered attention. It was initially identified as one of the upregulated miRs in human retinoblastoma tissues and Waldenström macroglobulinemia cells. 8, 9 In addition, increased levels of miR-494 were observed in myocardial microvascular endothelial cells from type 2 diabetic Goto-Kakizaki rats compared with Wistar rats. 10 However, miR-494 was downregulated in head and neck squamous cell carcinoma primary tissue. 11 Interestingly, overexpression of miR-494 suppressed the proliferation of head and neck squamous cell carcinoma cells, whereas inhibition of miR-494 stimulated their growth. 11 These data suggest that miR-494 may be involved in the initiation and progression of tumor pathogenesis. Recently, several miR profiling studies revealed that miR-494 was downregulated in human failing hearts and animal ischemic/hypertrophic hearts. [12] [13] [14] However, in ex vivo I/R mouse hearts, we observed that miR-494 levels were significantly increased. 15 Therefore, it would be very interesting to elucidate the possible roles of miR-494 in I/R-induced cardiac injury.
In the present study, we generated a mouse model with cardiac-specific overexpression of miR-494 to determine its functional significance in I/R-induced myocardial damage. In parallel, we acutely expressed miR-494 in adult rat cardiomyocytes by infection with a recombinant adenovirus that contains primary miR-494 DNA and subjected these cells to simulated I/R challenge. For the first time, we demonstrate that increased miR-494 levels protect hearts against I/Rtriggered injury; conversely, knockdown of endogenous miR-494 by antisense oligonucleotide (antagomiR) sensitized hearts to I/R-induced injury. Using multiple target prediction software, Western blot analysis, and a luciferase reporter assay, we identified that miR-494 targeted not only proapoptotic proteins (PTEN, ROCK1, and CaMKII␦) but also antiapoptotic proteins (FGFR2 and LIF). Intriguingly, these proapoptotic/antiapoptotic proteins regulate a common downstream Akt-mitochondrial signaling pathway. Our study further revealed that the Akt signaling was activated in miR-494 transgenic (TG) hearts, which may contribute to its salutary effects on I/R. Thus, miR-494 may constitute a new therapeutic agent for the treatment of ischemic heart disease.
Methods
An expanded Materials and Methods section that includes regional ischemia in vivo, miR extraction and quantitative real-time polymerase chain reaction (PCR), global ischemia ex vivo, cardiac injury (necrosis and apoptosis) analysis, construction of adenovirus vectors, preparation of adult rat cardiomyocytes, simulated I/R treatment, and Western blot analysis is available in the online-only Data Supplement. All animal protocols conformed to the Guidelines for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health and were approved by the University of Cincinnati Animal Care and Use Committee.
Generation of a miR-494 TG Mouse Model
TG mice (FVB/N) were constructed by use of a 372-bp DNA fragment containing murine primary miR-494 DNA under the control of the ␣-myosin heavy chain promoter. Expression levels of miR-494 in TG hearts were detected by Northern blot as previously described. 15 U6 was used as a loading control to normalize expression levels. The MiR-494 probe sequence was 5Ј-GAG GTT TCC CGT GTA TGT TTC A-3Ј. The U6 probe sequence was 5Ј-GCA GGG GCC ATG CTA ATC TTC TCT GTA TCG-3Ј.
Luciferase Reporter Assay for miR-494 Targets
For luciferase reporter experiments, a ROCK1, PTEN, CAMKII␦, FGFR2, LIF, or Api5 3Ј untranslated region (UTR) segment of Ϸ120 bp and its respective mutant (all primer sequences are listed in the online-only Data Supplement) were amplified by footprint 2-step PCR ( Figure I in the online-only Data Supplement) and inserted into the pMIR-REPORT luciferase miR expression reporter vector (Ambion, Austin, Tex) ( Figure II in the online-only Data Supplement). HEK293 cells were cotransfected in 12-well plates with Dharma-FECT Duo transfection reagent (Thermo Fisher Scientific Inc, Milford, Mass) according to the manufacturer's instructions, with 0.4 g of the 3Ј UTR luciferase reporter vector and 0.08 g of the control vector pMIR-␤-galactosidase (Ambion). Cell lysates were prepared 48 hours later; luciferase activity was measured with a Monolight 3010 luminometer (Pharmingen, San Diego, Calif) and expressed as relative light units with a luciferase assay kit (Promega, Madison, Wis). ␤-Galactosidase activity was measured with a commercially available kit (Promega). 3Ј UTR activity of each construct was expressed as the ratio of luciferase to ␤-galactosidase activity. All transfections were performed in triplicate from 3 independent experiments.
In Vivo Administration of AntagomiR-494
Chemically modified antagomiRs have been used to inhibit miR expression in vivo. 15, 16 AntagomiRs were synthesized by Dharmacon (Lafayette, Colo). Sequences are 5Ј-g S a S gguuucccguguauguu S u S c S a S -Chol-3Ј (antagomiR-494) and 5Ј-g S a S gguuucccguguuacug S g S a S c S -Chol-3Ј (antagomiR-494 mutant as a control). Lower-case letters represent 2Ј-O-methyl-modified oligonucleotides; the subscript s represents a phosphorothioate linkage; Chol represents linked cholesterol; and italicized letters are a mutated seed sequence. AntagomiR oligonucleotides were deprotected, desalted, and purified by highperformance liquid chromatography. Male FVB/N mice (6 weeks old) received antagomiR-494, mutant antagomiR-494, or a comparable volume of saline (200 L) through 3 consecutive daily injections via the tail vein (3ϫ 40 mg/kg body weight). Global no-flow I/R was performed on the third day after the final injection.
Statistical Analysis
Data are expressed as meanϮSD. ANOVA was conducted first across all investigated groups in measurements of myocardial function during ex vivo I/R, in which we performed the Shapiro-Wilk test for normality, and there was no evidence of deviation from normality for all variables. Then, posthoc pairwise tests were performed with assessment of statistical significance after Bonferroni correction of P values. At ␣ϭ0.05, only a value from pairwise test for each time point of PϽ0.05/6ϭ0.008 would be considered significant. PϽ0.05 was considered statistically significant when the Student t test was used for 2-group comparisons in other figures.
Results

Expression Levels of miR-494 in Murine Hearts on I/R In Vivo and Ex Vivo
Although several studies have reported the signature of miR expression profiles in diseased hearts, some miRs demonstrated conflicting alterations in their expression levels between ischemic and hypertrophic hearts. [12] [13] [14] [15] [16] [17] [18] [19] [20] For example, levels of miR-1, miR-181b, and miR-30 are increased in ischemic hearts but decreased in hypertrophic hearts ( Figure  1A ). Levels of miR-208, miR-320, and miR-351 are downregulated in ischemic hearts but upregulated in hypertrophic hearts ( Figure 1A) . Nonetheless, several miRs demonstrated a similar alteration pattern such as miR-21 and miR-214 (upregulated) and miR-494 and miR-185 (downregulated) in both ischemic and hypertrophic hearts ( Figure 1A ). In the present study, we focused our measurements on miR-494 by stem-loop real-time PCR in both in vivo and ex vivo I/R hearts ( Figure 1B and 1C and Figure III in the online-only Data Supplement). Compared with a sham group, levels of miR-494 were increased by 1.6Ϯ0.2-fold in 30-minute left anterior descending artery occluded hearts and kept increas-ing by 2.1Ϯ0.4-fold at 1 hour of reperfusion. Then, miR-494 returned to basal levels at 4 hours of reperfusion and further decreased by 66% in the myocardium at 24 hours of reperfusion ( Figure 1B ). In hearts subjected to 45 minutes of ischemia ex vivo, miR-494 levels were increased by 2.6Ϯ0.4fold and further increased by 3.2Ϯ0.5-fold after 2 hours of reperfusion ( Figure 1C ). These findings indicate that alteration of miR levels is dynamic and dependent on the physiological/pathological conditions. Our results suggest that downregulation of miR-494 may be involved in I/Rinduced myocardial damage, whereas transient upregulation of miR-494 may represent an adaptive response to I/R challenge.
Generation and Characterization of an miR-494 TG Mouse Model
MiR-494 is predicted to have hundreds of potential targets (mouse miR-494 has 245 targets and human miR-494 has 360 targets; TargetScan 5.1, 2009, http://www.targetscan.org). More important, these assumed targets include both well-characterized proapoptotic (SOCS6, PTEN, ROCK1, CAMKII␦, etc) and antiapoptotic (FGFR2, LIF, Api5, IGF1R, FGF7, etc) proteins. Therefore, it is necessary to evaluate the long-term and global consequences of miR-494 overexpression in adult hearts. We used a cardiac-specific promoter to drive the expression of a 372-bp primary miR-494 ( Figure 2A ). Northern blot analysis ( Figure 2B ) revealed that miR-494 was successfully overex- Figure 1 . Expression levels of miR-494 were dynamically regulated in I/R hearts. A, Summary of miR expression profiles in ischemic and hypertrophic hearts. [12] [13] [14] [15] [16] [17] [18] [19] [20] B, Dynamic alteration of miR-494 expression in the heart subjected to in vivo 30-minute ischemia followed by reperfusion. C, miR-494 was upregulated in ex vivo hearts subjected to 45-minute ischemia followed by 2-hour reperfusion. *PϽ0.01 vs sham controls (nϭ5 for sham and ischemic group; nϭ3 for 1-hour, 4-hour, and 24-hour reperfusion groups; nϭ4 for 45-minute ischemia and 2-hour reperfusion groups).
Figure 2.
Models of cardiac-specific overexpression of miR-494 showed no apparent cardiac morphological, physiological, or pathological abnormalities. A, Diagram of miR-494 TG vector. B, miR-494 expression was detected by Northern blot. U6 was used as an internal control (nϭ4). C, Ratio of heart weight to body weight (HW/BW) was similar between WT and miR-494 TG mice. PϾ0.1 (nϭ14). D through G, Myocardial contractile function (LVDP, ϮdP/dt, and LVEDP) showed no difference between WT and miR-494 TG hearts. PϾ0.1 vs WT (nϭ12, WT; nϭ6 for each TG line). 
Overexpression of miR-494 Improves the Postischemic Recovery of Cardiac Function
Next, we determined the effects of miR-494 overexpression on postischemic injury. To exclude the involvement of inflammatory components during reperfusion, we used an isolated perfused-heart preparation. Both TG and WT hearts were subjected to 45 minutes of global no-flow ischemia followed by 1 hour of reperfusion. On I/R, TG hearts exhibited significantly better functional recovery than WT hearts (Figure 3 ), as determined by the rates of contraction ( Figure 3A ), relaxation ( Figure  3B ), and left ventricular developed pressure (LVDP; Figure 3C ). In addition, the left ventricular end-diastolic pressure (LVEDP) was significantly depressed in miR-494 hearts during reperfusion compared with WT controls ( Figure 3D ). Together, these data reveal that increased levels of miR-494 (2.3-to 7.5-fold) are associated with improved cardiac functional recovery on ex vivo I/R. Notably, TG hearts with 2.3Ϯ0.3-fold overexpression of miR-494 (line 4) showed effects similar to TG hearts with 5.9Ϯ0.4-fold (line 7) and 7.6Ϯ0.6-fold (line 8) overexpression of miR-494 in response to I/R, pointing to the complexity of miR dosage in vivo. However, these gene-dosage effects are consistent with other reports using transgenesis; eg, TG hearts with 2.5-fold overexpression of Sirt1 exhibited resistance against oxidative stress similar to hearts with 7.5-fold overexpression. 21
Overexpression of miR-494 Reduces I/R-Induced Cardiac Injury
It is well appreciated that maintaining adequate numbers of myocytes is critical to the overall preservation of cardiac structural integrity and function after I/R. [22] [23] [24] Given the markedly improved recovery of myocardial function in miR-494 hearts, we next determined the effects of miR-494 on postischemic cellular damage. The extent of necrotic and apoptotic cell death was examined after ex vivo ischemia for 45 minutes followed by 1 hour of reperfusion. Under basal conditions, release of lactate dehydrogenase (LDH), a biochemical marker for necrotic cell death, did not differ between miR-494 hearts and WT controls (data not shown). However, on I/R, LDH release was significantly suppressed by Ϸ40% in miR-494 hearts compared with WT hearts ( Figure 4A ). These results indicate that overexpression of miR-494 inhibits I/R-initiated cellular disruption in the myocardium. Furthermore, heart lysates from a subset of experimental animals were assayed for histone-associated DNA fragmentation, which exhibited an Ϸ50% decrease in miR-494 hearts over WT hearts ( Figure 4B) . Additionally, the number of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive nuclei was significantly reduced in the I/R miR-494 myocardium (line 4, 2.5Ϯ1.1%; line 7, 1.6Ϯ1.0%; line 8, 2.1Ϯ1.3%) relative to WT controls (5.9Ϯ2.4%; nϭ5; PϽ0.05; Figure 4C and 4D) . Moreover, the activity of caspase-3 was decreased by Ϸ40% in miR-494 hearts on I/R relative to WT hearts ( Figure 4E ). Therefore, all 3 assays (DNA fragmentation, TUNEL assay, and caspase-3 activity) demonstrate that overexpression of miR-494 protects the myocardium against I/R-induced cellular damage.
To further determine the consequence of increased miR-494 expression under in vivo conditions, we subjected WT and TG hearts to in vivo 30-minute myocardial ischemia via coronary artery occlusion followed by 24-hour reperfusion. We observed that the ratio of infarct to risk region was 10.2Ϯ3.3% in line 4 hearts (nϭ6) and 7.6Ϯ2.4% in line 7 hearts (nϭ11) compared with 24Ϯ3.2% in WT hearts (nϭ10; Figure 3 . MiR-494 hearts showed improved functional recovery (A through D) after 45-minute ischemia followed by 1-hour reperfusion. *PϽ0.008 vs WT (nϭ12 for WT; nϭ6 for each TG line).
PϽ0.001), whereas the region at risk was not significantly different between groups ( Figure 4F ). These results are consistent with our ex vivo findings that miR-494 has cardioprotective effects on I/R-induced injury.
miR-494 Downregulates Expression of Both Proapoptotic and Antiapoptotic Proteins
To elucidate the potential mechanism(s) of miR-494 -mediated cardioprotection, we assessed expression levels of miR- 494 targets in TG hearts. Theoretically predicted by TargetScan, miRDB, and PicTar, miR-494 has hundreds of potential targets that were surprisingly divided into 2 subgroups: proapoptotic and antiapoptotic proteins. Considering the importance of these candidates in ischemic heart disease, we selected the following putative targets for Western blot analysis (proapoptotic: ROCK1, PTEN, and CAMKII␦; antiapoptotic: FGFR2, LIF, and Api5). As expected, the levels of proteins ROCK1, PTEN, CAMKII␦, FGFR2, and LIF were significantly decreased in miR-494 TG hearts compared with WT hearts ( Figure 5 and Figure V in the online-only Data Supplement). However, Api5 was not downregulated, although it is predicted to be a target of miR-494 by seed-sequence matching ( Figure 5B and Figure VI in the online-only Data Supplement). Therefore, our findings suggest that some predicted targets are not authentic. Actually, accumulating evidence has suggested that perfect seed pairing may not necessarily be a reliable predictor for miR-messenger RNA (mRNA) interaction because these bioinformatics tools do not consider mRNA secondary structures that may affect miR target recognition. 25 It is well documented that inhibition/downregulation of ROCK1, PTEN, and CAMKII␦ by either pharmacological or genetic approaches improves myocardial survival after I/R injury. Furthermore, these beneficial effects were associated mainly with activation of the prosurvival Akt pathway. 26 -29 On the other hand, both LIF and FGFR2 have been shown to be survival signal mediators in cardiomyocyte response against (A and B) . These 6 targets were predicted by TargetScan (see the online-only Data Supplement). C, The Akt-mitochondrial signaling was activated, as evidenced by increased phosphorylated Akt (S473), phosphorylated Bcl-2-associated death promoter (BAD) (S136), Bcl-xL, and Bcl-2 levels in miR-494 TG hearts. *PϽ0.001 vs WT controls (nϭ5). myocardial infarction. 30 -32 More interesting, protective effects of LIF and FGFR2 were also related to upregulation of the Akt signaling. 30 -32 Hence, we next examined whether the Akt signaling was activated or inhibited in miR-494 TG hearts. As shown in Figure 5C , although the total Akt was not altered, levels of phosphorylated Akt (T308 and S473) were increased by Ϸ2-fold in miR-494 hearts relative to WT controls. Accordingly, Bcl-2-associated death promoter (BAD), a downstream target of Akt, was greatly activated in miR-494 hearts, as evidenced by an 8-to 10-fold increase in levels of phosphorylated Bcl-2-associated death promoter (BAD). Furthermore, the mitochondrial signaling molecules Bcl-xL and Bcl-2 were upregulated in miR-494 TG hearts compared with WT samples ( Figure 5C ). Together, these findings reveal that although miR-494 targets both proapoptotic kinases and antiapoptotic growth factors/receptors, as indicated above, the ultimate consequence of miR-494 is activation of the Akt-mitochondrial signaling pathway in the myocardium.
miR-494 Directly Targets at 3 UTRs of both Proapoptotic and Antiapoptotic Proteins
To further validate whether miR-494 directly recognizes 3Ј UTRs of ROCK1, PTEN, CAMKII␦, FGFR2, LIF, and Api5, we generated luciferase reporter constructs harboring a segment of ROCK1, PTEN, CAMKII␦, FGFR2, LIF, or Api5 3Ј UTR. Their respective mutant constructs contained a mutated seed sequence (see the primer list and Figure II in the online-only Data Supplement). These luciferase reporter constructs were cotransfected into HEK293 cells with either miR-494 or miR control. ␤-Galactosidase vector was also cotransfected as an internal control. Forty-eight hours after transfection, we conducted luciferase activity assays and observed that cotransfection of miR-494 strongly inhibited the luciferase activity from the reporter construct containing the 3Ј UTR segment of ROCK1, PTEN, CAMKII␦, FGFR2, or LIF, whereas no effect was observed with their corresponding mutated constructs ( Figure 6 ). This effect was specific because there was no change in the luciferase reporter activity when a negative control miR was cotransfected with either reporter construct ( Figure 6 ). Consistent with the above Western blot data, luciferase activity was not altered in cells cotransfected with miR-494 and the reporter vector of Api5-3Ј UTR ( Figure 6 ). Collectively, these results indicate that transcripts of ROCK1, PTEN, CAMKII␦, FGFR2, and LIF may represent genuine targets of miR-494, whereas Api5, albeit predicted, appears to be a false target of miR-494.
miR-494 Protects Against Simulated I/R-Induced Cardiomyocyte Death In Vitro
Considering that long-term overexpression of miR-494 in vivo may have compensatory effects that influence the consequence of miR-494 in the ischemic myocardium, we performed further studies using ex vivo cultured adult cardiomyocytes, a wellcontrolled experimental setting. Cardiomyocytes were infected with adenovirus (Ad) miR-494 and Ad␤-galactosidase ( Figure  7A ). After infection for 48 hours, we observed a nearly 95% infection efficiency ( Figure 7B ). Importantly, there were no apparent morphological alterations or differences in the number of adherent cells and rod-shaped cells between AdmiR-494 -and Ad␤-galactosidase-infected groups (Figure 7B ). Real-time PCR revealed that miR-494 was overexpressed by 3-fold in AdmiR- Figure 7C ), which resulted in the downregulation of ROCK1, PTEN, CAMKII␦, FGFR2, and LIF ( Figure 7D ). As a consequence, Akt was activated in miR-494 cells ( Figure 7D ). These data further validate the above in vivo results (Figures 5A, 5B, and 6 ). We next examined the effects of miR-494 on cell survival on 1-hour simulated ischemia followed by 3-hour reperfusion. Cell viability analysis showed that ectopic expression of miR-494 increased cell survival by 40Ϯ3% relative to ␤-galactosidase cells ( Figure 7E ). Furthermore, on I/R, AdmiR-494 -infected myocytes exhibited a significant decrease in histone-associated DNA fragmentation compared with Ad␤-galactosidase-infected myocytes (28Ϯ3% versus 41Ϯ1%; Figure 7F ). Caspase-3 activity in cell lysates on I/R was consistently reduced significantly in miR-494 cells compared with controls ( Figure 7G ). Taken together, these data indicate that ROCK1, PTEN, CAMKII␦, FGFR2, and LIF are downregulated by short-term expression of miR-494, contributing to attenuation of I/R-induced cell damage.
-infected cardiomyocytes (
Knockdown of miR-494 Renders the Heart More Sensitive to I/R Injury
To recapitulate the in vivo setting that miR-494 is downregulated in the heart after I/R, we treated mice with an antagomiR-494 via 3 consecutive daily tail vein injections of cholesterol-modified antagomiR-494 (3ϫ 40 mg/kg). Mutated antagomiR-494 and saline were used as controls. Three days after the last administration of antagomiR-494, stem-loop real-time PCR showed a 60Ϯ5% reduction in miR-494 expression in the heart tissue ( Figure 8A) . In contrast, the mutated antagomiR-494 had no effect on the expression level of miR-494 compared with the saline control ( Figure 8A) . These results indicate that antagomiR treatment efficiently downregulates miR-494 expression in the heart, consistent with previous reports with antagomiRs. 15, 16 Consequently, administration of antagomiR-494, but not the antagomiR-494 mutant, yielded the upregulation of ROCK1, PTEN, CAMKII␦, FGFR2, and LIF in the myocardium, which ultimately reduced Akt activation (Figure 8B) . Furthermore, we observed that antagomiR-treated hearts exhibited significantly depressed functional recovery during ex vivo I/R (45 minutes/1 hour), evidenced by decreased rates of contraction (dP/dt), relaxation (ϪdP/dt), and LVDP in antagomiR-494 hearts relative to controls ( Figure 8C through 8E). In addition, treatment with antagomiR-494 led to 5.2Ϯ0.9-fold increases in LDH release during reperfusion relative to antagomiR mutant-and saline-treated hearts ( Figure 8F) . Similarly, knockdown of endogenous miR-494 by antagomiR increased cardiac DNA fragmentation and caspase-3 activity by 1.3Ϯ0.02-fold and 1.2Ϯ0.08-fold, respectively, compared with controls on I/R ( Figure  8G and 8H) . Collectively, these data indicate that reduced endogenous levels of miR-494 sensitize the heart to I/R-induced injury.
Discussion
In recent years, tremendous effort has been made to use an miR microarray screening approach to address the miR expression .001 vs saline-and mutanttreated controls (nϭ4). B, Protein levels of ROCK1, PTEN, CAMKII␦, FGFR2, and LIF were increased in antagomiR-494 -treated hearts. Consequently, Akt was inactivated by reduced levels of phosphorylated Akt (T308 and S473). C through E, AntagomiR-494 treatment suppressed cardiac functional recovery during ischemia/reperfusion compared with saline-and mutant-treated controls. *PϽ0.008 (nϭ4). F, Total LDH in coronary effluent collected during the first 10 minutes of reperfusion was significantly increased in antagomiR-494 -treated hearts compared with controls. *PϽ0.001 (nϭ4). The degree of histone-associated DNA fragmentation (G) and caspase-3 activity (H) was increased in antagomiR-494 hearts subjected to ex vivo 45-minute ischemia followed by 1-hour reperfusion. *PϽ0.04 vs saline-and mutant-treated controls (nϭ4). I, Overexpression of miR-494 downregulates both proapoptotic and antiapoptotic proteins, which ultimately tilts the balance of a downstream Akt-mitochondrial signaling pathway toward activation, leading to cardioprotection against I/R-induced injury.
profiling in infarcted hearts from animal models and human patients. 14 -20 However, the role of a specific miR in ischemic heart disease is just emerging. In the present study, we focus on elucidating the functional consequences of miR-494 in vivo using gain-of-function and loss-of-function approaches. Although miR-494 has been reported to be downregulated in the hypertrophic heart, 18 long-term overexpression of miR-494 in vivo did not yield any cardiac morphological or pathological abnormalities (Figure 2 and Figure IV in the online-only Data Supplement). More exciting, we observed that miR-494 -overexpressing hearts were resistant to I/R-induced injury in vivo and ex vivo, whereas knockdown of endogenous miR-494 by antagomiR showed the opposite effect. Taken together, these data clearly demonstrate that increased levels of miR-494 render cardioprotection against I/R injury. Our study also suggests that the downregulation of miR-494 observed in human patients 14 may be causally involved in the progression of heart failure, at least in part.
A prominent characteristic of miR-494 is that it potentially regulates both antiapoptotic (eg, CDK6, FGFR2, IGF2BP1, XIAP, HLF, LIF, API5, FGF7, IGF1R, and HDGF) and proapoptotic (eg, SOCS6, PTEN, ROCK1, PPARGC1␣, and CAMKII␦) proteins. Therefore, it is plausible that miR-494 may function as either proapoptotic or antiapoptotic, depending on the cellular environment and cell-specific expressed targets. For instance, in JHU-021 cancer cells, transfection of miR-494 induced cell death, indicating its proapoptotic role, 11 although the underlying mechanisms remain unknown. In cardiomyocytes, our results have implicated miR-494 as an antiapoptotic miR via activation of the Akt signaling pathway. Although we did verify that 3 proapoptotic proteins (PTEN, ROCK1, and CAMKII␦) and 2 antiapoptotic proteins (FGFR2 and LIF) were bona fide targets of miR-494, the individual contribution of these targets to the downstream Akt pathway may be unequal. In miR-494 -overexpressing cardiomyocytes, the impact of PTEN, ROCK1, and CAMKII␦ (either individually or in combination) on the Akt signaling may be more significant than the impact of FGFR2, LIF, or other antiapoptotic targets, thereby tilting the balance of the Akt pathway toward activation ( Figure 8I ). These interesting findings suggest that divergent targets of a miR may work unequally to balance a common signaling pathway and eventually affect its functional consequences.
In addition, we performed mRNA array analysis for miR-494 TG hearts and observed that a total of 685 mRNAs were significantly altered (upregulated, 292; downregulated, 393; Tables I and II in the online-only Data Supplement) . Surprisingly, among these 685 mRNAs, only 6 are predicted to be targets of miR-494 by TargetScan. More intriguing, mRNA levels of PTEN, ROCK1, CAMKII␦, FGFR2, and LIF showed no alteration ( Table III in the online-only Data Supplement), whereas their protein levels were downregulated in miR-494 cardiomyocytes. The inconsistency between mRNA and protein levels suggests that the long-term miRoverexpressing model may have limitations when using conventional mRNA expression arrays to detect miR targets. Another possibility may be that miR-494 dampens target protein levels mostly by impeding their translation rather than by breaking down their messenger RNAs. Notably, a recent study using human bronchial epithelial cells 33 showed that miR-494 regulated PTEN protein expression but not mRNA levels, which is consistent with our present findings. To further identify the whole target network for miR-494, a new technique called SILAC (stable isotope labeling with amino acids in cell culture) 34, 35 will be an ideal tool; however, such an analysis falls outside the scope and intent of this study.
Currently, it is well accepted that inhibition of PTEN, ROCKs, or CaMKII has a major impact on improving myocardial survival after an I/R episode. 26 -29 Although several pharmacological agents can effectively inhibit PTEN, ROCKs, or CaMKII, these inhibitors may be toxic in physiological settings, and their clinical applications may be restricted. 36, 37 Thus, identifying novel substitutes that orchestrate suppression of PTEN, ROCKs, and CaMKII in the myocardium is very important. In the present study, we clearly showed that overexpression of miR-494 reduced the levels of PTEN, ROCK1, and CaMKII␦, which might work in concert to activate Akt signaling, a critical survival pathway in the myocardium. However, it may be experimentally complicated to link PTEN, ROCK1, and CaMKII␦ together for elucidating mechanisms underlying the protective effects of miR-494 against I/R. Further studies are needed to ascertain the causal relationship between miR-494 -modulated targets and their functional consequences.
Conclusions
To the best of our knowledge, this is the first report to demonstrate that the protective role of miR-494 in I/R is mediated, at least in part, by the activation of Akt-mitochondrial signaling. The present observations expand our understanding of miRs associated with ischemic heart disease and may provide a basis for novel therapeutic strategies aimed at enhancing cardiomyocyte survival in the ischemic myocardium.
